How should clinicians approach the decision to stop apixaban in cases of per vagina bleed, considering thrombotic risks, bleeding severity, and potential interventions?
Tripdatabase;
How should clinicians approach the decision to stop apixaban in cases of per vagina bleed, considering thrombotic risks, bleeding severity, and potential interventions?
Clinicians need to balance bleeding management against thrombotic risks when considering stopping apixaban due to vaginal bleeding, using reversal agents like andexanet alfa judiciously to reverse anticoagulation during serious bleeding events.